HIV and placental infection modulate the appearance of drug-resistant Plasmodium falciparum in pregnant women who receive intermittent preventive treatment

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 41-48

  Menéndez, Clara ^a,b   Serra Casas, Elisa ^a,b   Scahill, Michael D ^b,d   Sanz, Sergi ^a   Nhabomba, Augusto ^b   Bardají, Azucena ^a,b   Sigauque, Betuel ^b,c   Cisteró, Pau ^a   Mandomando, Inacio ^b,c   Dobaño, Carlota ^a,b   Alonso, Pedro L ^a,b   Mayor, Alfredo ^a,b  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b MINISTRY OF HEALTH   (Mozambique)

^c INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; MOLECULAR MARKER; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE;

ADULT; ALLELE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INTERMITTENT PREVENTIVE TREATMENT; MAJOR CLINICAL STUDY; MALARIA; MORBIDITY; MOTHER; MOZAMBIQUE; NONHUMAN; PARASITE; PATHOGEN CLEARANCE; PLACENTA DISORDER; PLACENTITIS; PLASMODIUM FALCIPARUM; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THIRD TRIMESTER PREGNANCY;

ADULT; ALLELES; ANTIMALARIALS; CHEMOPREVENTION; DNA, PROTOZOAN; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; GENETIC MARKERS; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALARIA, FALCIPARUM; MOZAMBIQUE; PLACEBOS; PLACENTA; PLASMODIUM FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMETHAMINE; SULFADOXINE;

EID: 79951651049     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq049     Document Type: Article

References (37)

1. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ 1983;61(6); 1005-1016. (Pubitemid 14181621)
2. White NJ, McGready RM, Nosten FH. New medicines for tropical diseases in pregnancy: catch-22. PLoS Med 2008;5(6); e133.
3. Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 2007;7(2); 136-144. (Pubitemid 46123134)
4. Yamada M, Steketee R, Abramowsky C, et al. Plasmodium falciparum associated placental pathology: a light and electron microscopic and immunohistologic study. Am J Trop Med Hyg 1989;41(2); 161-168. (Pubitemid 19224757)
5. Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004;363(9424); 1860-1867. (Pubitemid 38748641)
6. Rogerson SJ, Wijesinghe RS, Meshnick SR. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis 2010;10(1); 51-59.
7. Menendez C, Bardaji A, Sigauque B, et al. Malaria prevention with IPTp during pregnancy reduces neonatal mortality. PLoS One 2010;5(2); e9438.
8. World Health Organization (WHO). A strategic framework for malaria prevention and control during pregnancy in the African region. Brazzaville, Congo: WHO Regional Office for Africa, 2004.
9. Karunajeewa HA, Salman S, Mueller I, et al. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother 2009;53(10); 4368-4376.
10. Sibley CH, Hyde JE, Sims PF, et al. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 2001;17(12); 582-588. (Pubitemid 34088118)
11. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002;185(3); 380-388. (Pubitemid 34107252)
12. Mockenhaupt FP, Bedu-Addo G, Junge C, Hommerich L, Eggelte TA, Bienzle U. Markers of sulfadoxine-pyrimethamine-resistant Plasmodium falciparum in placenta and circulation of pregnant women. Antimicrob Agents Chemother 2007;51(1); 332-334. (Pubitemid 46047723)
13. Mockenhaupt FP, Bedu-Addo G, Eggelte TA, et al. Rapid increase in the prevalence of sulfadoxine-pyrimethamine resistance among Plasmodium falciparum isolated from pregnant women in Ghana. J Infect Dis 2008;198(10); 1545-1549.
14. Bouyou-Akotet MK, Mawili-Mboumba DP, Tchantchou Tde D, Kombila M. High prevalence of sulfadoxine/pyrimethamine-resistant alleles of Plasmodium falciparum isolates in pregnant women at the time of introduction of intermittent preventive treatment with sulfadoxine/pyrimethamine in Gabon. J Antimicrob Chemother 2010;65(3); 438-441.
15. Harrington WE, Mutabingwa TK, Muehlenbachs A, et al. Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment. Proc Natl Acad Sci U S A 2009;106(22); 9027-9032.
16. Alonso P, Saute F, Aponte JJ, et al. Manhica demographic surveillance System, Mozambique. Population, Health and Survival at INDEPTH Sites 2001;1:189-195.
17. Menendez C, Bardaji A, Sigauque B, et al. A randomized placebocontrolled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic. PLoS One 2008;3(4); e1934.
18. Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994;344(8931); 1175-1181. (Pubitemid 24323705)
19. Ismail MR, Ordi J, Menendez C, et al. Placental pathology in malaria: a histological, immunohistochemical, and quantitative study. Hum Pathol 2000;31(1); 85-93. (Pubitemid 30054392)
20. Mayor A, Serra-Casas E, Bardaji A, et al. Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. Malar J 2009;8:9.
21. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997;176(6); 1590-1596. (Pubitemid 27518161)
22. Snounou G, Zhu X, Siripoon N, et al. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 1999;93(4); 369-374. (Pubitemid 29405860)
23. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 2003;270(1514); 545-554. (Pubitemid 36308233)
24. Jafari-Guemouri S, Ndam NT, Bertin G, et al. Demonstration of a high level of parasite population homology by quantification of Plasmodium falciparum alleles in matched peripheral, placental, and umbilical cord blood samples. J Clin Microbiol 2005;43(6); 2980-2983. (Pubitemid 40827992)
25. Diouf I, Fievet N, Doucoure S, et al. IL-12 producing monocytes and IFN-gamma and TNF-alpha producing T-lymphocytes are increased in placentas infected by Plasmodium falciparum. J Reprod Immunol 2007;74(1-2); 152-162. (Pubitemid 46695854)
26. Diouf I, Fievet N, Doucoure S, et al. Monocyte activation and T cell inhibition in Plasmodium falciparum-infected placenta. J Infect Dis 2004;189(12); 2235-2242. (Pubitemid 38757196)
27. Riley EM, Schneider G, Sambou I, Greenwood BM. Suppression of cellmediated immune responses to malaria antigens in pregnant Gambian women. Am J Trop Med Hyg 1989;40(2); 141-144. (Pubitemid 19086538)
28. Hastings IM, Donnelly MJ. The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist Updat 2005;8(1-2); 43-50. (Pubitemid 40797955)
29. Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJ, Watkins WM. Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation. Am J Trop Med Hyg 2005;73(1); 166-170. (Pubitemid 41278766)
30. Mayor A, Serra-Casas E, Sanz S, et al. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis 2008;197(12); 1737-1742. (Pubitemid 351919639)
31. Djimde AA, Doumbo OK, Traore O, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 2003;69(5); 558-563. (Pubitemid 38248261)
32. Marks F, von Kalckreuth V, Kobbe R, et al. Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine. J Infect Dis 2005;192(11); 1962-1965. (Pubitemid 41681894)
33. Gesase S, Gosling RD, Hashim R, et al. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. PLoS One 2009;4(2); e4569.
34. Chawira AN, Warhurst DC, Peters W. Qinghaosu resistance in rodent malaria. Trans R Soc Trop Med Hyg 1986;80(3); 477-480.
35. Nkhoma S, Molyneux M, Ward S. Molecular surveillance for drugresistant Plasmodium falciparum malaria in Malawi. Acta Trop 2007;102(2); 138-142. (Pubitemid 46898951)
36. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14(7); 353-356. (Pubitemid 23198169)
37. Steketee RW, Wirima JJ, Bloland PB, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996;55(suppl 1); 42-49.